Initially, patients will be enrolled concurrently into 4 exploratory cohorts, which will include patients with relapsed SCLC, gBRCAm metastatic HER2-negative breast cancer, gBRCAm platinum-sensitive relapsed ovarian cancer, and gastric cancer. Additional tumor types may be added at a later date based on emerging data. The results from this study will form decision-making for future studies.